GVR Report cover Blood Glucose Monitoring Devices Market Size, Share & Trends Report

Blood Glucose Monitoring Devices Market Size, Share & Trends Analysis Report By Product (Self-Monitoring Devices, Continuous Blood Glucose Monitoring Devices), By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-3-68038-688-2
  • Number of Pages: 110
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global blood glucose monitoring devices market size was valued at 11.71 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2030. The key drivers of the market are the rising incidence of diabetes and the increasing geriatric population prone to diabetes. The market growth is further propelled by the increasing awareness regarding diabetes preventive care and new product launches. Diabetes is a serious and growing problem globally, where the inefficiency of the pancreas to produce insulin results in an increase in blood glucose levels. According to the International Diabetes Federation, in 2021, around 537 million people were diagnosed with diabetes, this number is expected to increase to 643 million by 2030 and 783 million by 2045.

 U.S. blood glucose monitoring devices market size, by product, 2020 - 2030 (USD Billion)

Blood glucose monitoring (BGM) devices are helpful for patients with diabetes in four ways. These devices enable patients and clinicians to detect high or low blood glucose levels, allowing for therapy modifications and protecting patients by confirming acute hypoglycemia or hyperglycemia promptly and by offering patients greater self-care. The technology facilitates patient education about diabetes and its management and encourages people to adopt healthier habits. Blood glucose devices are available in a multitude of sizes, prices, testing times, and ease of use.

The COVID-19 pandemic has opened new opportunities for blood glucose monitoring devices and these devices gained more popularity in the diabetic care market. Awareness regarding the benefits of blood glucose monitoring devices increased among the consumers as during the pandemic, there had been an emphasis on the use of virtual clinics and telemedicine for diabetic management. The blood glucose monitoring devices helped patients and healthcare providers improve glycemic control and potentially increase patient self-management, thus changing diabetes care significantly. Further, a surge in the demand for blood glucose monitoring devices due to the quick response by major market players during the Covid-19 pandemic.

The rapidly changing lifestyle such as the consumption of alcohol and smoking is contributing to the rise in the number of diabetes patients, worldwide. Obesity is also one of the major factors contributing to diabetes. Furthermore, the increasing geriatric population is propelling market growth. According to the WHO, by 2050, the world’s aging population will be about 2 billion from 1 billion in 2020.

End-use Insights

The hospital segment held the largest revenue share of over 40.0% in 2021 and is anticipated to lead the market over the forecast period due to the improving infrastructure and increasing healthcare expenditure in hospitals. Moreover, the reliable data that BGM devices provide practitioners in a fraction of seconds and the improvement in patients' quality of life have increased their adoption in the outpatient as well as inpatient hospital settings. Hospitals have additional provisions to store and transfer patient information. Furthermore, during the COVID-19 pandemic, the FDA allowed the use of CGM devices in hospitals, and the possibility of another pandemic in the future is expected to enhance the segment growth.

The home care segment is expected to register the fastest growth rate during the forecast period. The home-based glucose monitoring is revolutionized by the self-monitoring of blood glucose and is the most widely used method of short-term glucose monitoring throughout the world. The self-monitoring blood glucose (SMBG) is an approach through which people with or without diabetes can measure their blood sugar levels in their homes. Based on the reading, the patient can check the effects of their treatment such as diet, insulin, exercise, and stress management.

Product Insights

Self-monitoring blood glucose devices accounted for the largest revenue share of over 65.0% in 2021 owing to the ease of use and low cost. SMBG is considered an important element of diabetes management daily. Self-monitoring of blood sugar is an approach wherein people measure their blood sugar levels with the help of a glucose meter. It is sub-segmented into blood glucose meter, testing strips, and lancets. The testing strips segment accounted for the largest revenue share in 2021 owing to the high usage of these strips and affordability. The segment is expected to expand at a lucrative CAGR over the forecast period.

 Global self-monitoring devices market share, by product, 2021 (%)

The continuous blood glucose monitoring (CBGM) devices segment is expected to register the highest growth rate during the forecast period. CBGM is an important diabetes care tool for patients with type 1 diabetes, who are particularly vulnerable to severe and potentially life-threatening hypoglycemia. These devices help in analyzing the glucose level pattern as it provides continuous and real-time blood sugar reading every five minutes. It is sub-segmented into sensors, insulin pumps, and transmitter and receiver. CGM works through a tiny sensor that is inserted under the skin. This sensor measures sugar level and the transmitter wirelessly sends the information to a monitor. The transmitter and receiver segment held the largest revenue share in 2021.

Regional Insights

North America led the market with a revenue share of over 35.0% in 2021 owing to its well-established healthcare sector. The increasing prevalence of obesity, high cost of treatment, technological advancements, and new product launches are also expected to drive the regional market. Europe is expected to capture a significant revenue share over the forecast period due to an increase in the geriatric population, which is prone to diabetes. Moreover, improvements in the healthcare sector and the implementation of advanced medical products are augmenting the demand for BGMs in the region.

Asia Pacific is projected to be a lucrative region over the forecast period. Improvements in healthcare facilities and reimbursement policies in developing economies are key factors aiding the growth in this region. China spearheaded the APAC region in 2021 owing to its large diabetes population and rapid economic growth. Furthermore, an increase in awareness regarding diabetes preventive care is augmenting the market growth.

Key Companies & Market Share Insights

Major players are focusing on new product launches, government approvals, acquisitions, advancements in existing products & technologies, and other strategies to expand their business portfolio & strengthen their presence. For instance, In May 2021, Roche collaborated with Eli Lilly and Company, to work towards enhancing the management of insulin pen therapy. With this collaboration, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions, and services, across the continuum of care in diabetes. Some prominent players in the global blood glucose monitoring devices market include:

  • Abbott Laboratories

  • Medtronic plc

  • F. Hoffmann-La Roche Ltd.

  • Ascensia Diabetes Care

  • Dexcom, Inc.

  • Sanofi

  • Novo Nordisk

  • Insulet Corporation

  • Ypsomed Holdings

  • Glysens Incorporated

Blood Glucose Monitoring Devices Market Report Scope

              Report Attribute


Market size value in 2022

USD 12.53 billion

Revenue forecast in 2030

USD 23.15 billion

Growth rate

CAGR of 8.0% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Poland; Russia; Ukraine; Belarus; Turkey; China; Japan; India; Australia; South Korea; Kazakhstan; Uzbekistan; Mexico; Brazil; Colombia; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd.; Ascensia Diabetes Care; Dexcom, Inc.; Sanofi; Novo Nordisk; Insulet Corporation; Ypsomed Holdings; GlySens Incorporated

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report 

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global blood glucose monitoring devices market report based on product, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Self-monitoring Devices

      • Blood Glucose Meter

      • Testing Strips

      • Lancets

    • Continuous Blood Glucose Monitoring Devices

      • Sensors

      • Transmitter & Receiver

      • Insulin Pumps

  • End-use Outlook (Revenue, USD Million, 2017 - 2030)

    • Hospitals

    • Home Care

    • Diagnostic Centers

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Poland

      • Russia

      • Ukraine

      • Belarus

      • Turkey

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Kazakhstan

      • Uzbekistan

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon